1. Home
  2. AKBA vs FBIZ Comparison

AKBA vs FBIZ Comparison

Compare AKBA & FBIZ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Akebia Therapeutics Inc.

AKBA

Akebia Therapeutics Inc.

HOLD

Current Price

$1.42

Market Cap

380.4M

Sector

Health Care

ML Signal

HOLD

Logo First Business Financial Services Inc.

FBIZ

First Business Financial Services Inc.

HOLD

Current Price

$57.89

Market Cap

437.9M

Sector

Finance

ML Signal

HOLD

Company Overview

Basic Information
Metric
AKBA
FBIZ
Founded
2007
1909
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Major Banks
Sector
Health Care
Finance
Exchange
Nasdaq
Nasdaq
Market Cap
380.4M
437.9M
IPO Year
2014
2012

Fundamental Metrics

Financial Performance
Metric
AKBA
FBIZ
Price
$1.42
$57.89
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
4
4
Target Price
$5.25
$65.00
AVG Volume (30 Days)
2.3M
30.6K
Earning Date
05-07-2026
04-23-2026
Dividend Yield
N/A
2.41%
EPS Growth
93.94
14.23
EPS
N/A
5.94
Revenue
N/A
N/A
Revenue This Year
N/A
$15.69
Revenue Next Year
N/A
$8.47
P/E Ratio
N/A
$9.51
Revenue Growth
N/A
N/A
52 Week Low
$1.14
$43.61
52 Week High
$4.08
$60.54

Technical Indicators

Market Signals
Indicator
AKBA
FBIZ
Relative Strength Index (RSI) 54.02 69.64
Support Level $1.30 $53.56
Resistance Level $1.55 $59.60
Average True Range (ATR) 0.06 1.53
MACD -0.00 0.65
Stochastic Oscillator 67.65 90.04

Price Performance

Historical Comparison
AKBA
FBIZ

About AKBA Akebia Therapeutics Inc.

Akebia Therapeutics Inc is a fully integrated biopharmaceutical company. The Company's operating segment is the business of developing and commercializing novel therapeutics. The current portfolio of the company includes Auryxia (ferric citrate), a medicine approved and marketed in the United States for the control of serum phosphorus levels in adult patients with dialysis-dependent chronic kidney disease and the treatment of iron deficiency anemia, in adult patients with non-dialysis-dependent chronic kidney disease, Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, inhibitor approved in Japan for the treatment of anemia due to chronic kidney disease, and HIF-PH inhibitors in preclinical development.

About FBIZ First Business Financial Services Inc.

First Business Financial Services Inc operates as a bank holding company. The Bank operates as a business bank, delivering a full line of commercial banking products, including commercial loans and commercial real estate loans, to meet the specific needs of small and medium-sized businesses, business owners, executives, professionals, and high-net-worth individuals. The company's products and services include commercial lending, SBA lending and servicing, asset-based lending, equipment financing, factoring, trust, and investment services, treasury management services, and a broad range of deposit products. Geographically, all the business activity functioned through the region of the United States.

Share on Social Networks: